ABSTRACT
Objectives Patients with coronavirus disease 19 (COVID-19) are at high risk for fibrin-based occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as part of the COVID-19 thrombo-inflammatory storm, we aimed to find upstream mediators of this activation.
Methods Cultured endothelial cells were exposed to sera from 118 patients hospitalized with COVID-19. Cell adhesion molecules E-selectin, ICAM-1, and VCAM-1 were detected by in-cell ELISA. Soluble E-selectin was measured in serum.
Results We found modest correlations between serum NET remnants (cell-free DNA, myeloperoxidase-DNA complexes, citrullinated histone H3) and upregulation of surface E-selectin, VCAM-1, and ICAM-1 on endothelial cells. A stronger predictor of the ability of COVID-19 serum to activate endothelial cells was the presence of circulating antiphospholipid antibodies, specifically anticardiolipin IgG and IgM and anti-phosphatidlyserine/prothrombin (anti-PS/PT) IgG and IgM. Depletion of total IgG from anticardiolipin-high and anti-PS/PT-high samples markedly restrained upregulation of E-selectin, VCAM-1, and ICAM-1. At the same time, supplementation of control serum with patient IgG was sufficient to trigger endothelial cell activation.
Conclusions These data are the first to suggest that patient antibodies are a driver of endothelial cell activation in COVID-19 and add important context regarding thrombo-inflammatory effects of autoantibodies in severe COVID-19.
What is already known about this subject?
Patients with COVID-19 are at high risk for fibrin-based occlusion of vascular beds of all sizes. Endothelial cell activation has regularly been described as part of the COVID-19 thrombo-inflammatory storm.
What does this study add?
The presence of circulating antiphospholipid antibodies may be a predictor of the ability of COVID-19 serum to activate endothelial cells.
Purified COVID-19 IgG with high levels of anticardiolipin and anti-PS/PT activity trigger a pro-adhesive phenotype in endothelial cells.
How might this impact on clinical practice or future developments?
Patients might be screened for antiphospholipid antibodies to evaluate their risk of thrombosis and progression to respiratory failure.
Patients with high antiphospholipid antibody titers might benefit from treatments used in traditional cases of severe APS such as therapeutic anticoagulation, corticosteroids, and plasmapheresis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by a grant from the Rheumatology Research Foundation to JSK and grants from the Michigan Medicine Frankel Cardiovascular Center and A. Alfred Taubman Medical Research Institute to YK and JSK. YZ was supported by a career development grant from the Rheumatology Research Foundation and a grant from the Arthritis National Research Foundation. JAM was partially supported by the VA Healthcare System. JSK was supported by grants from the NIH (R01HL115138), Burroughs Wellcome Fund, and Lupus Research Alliance. YK was supported by the Intramural Research Program of the NIH and NHLBI, Lasker Foundation, NIH (R01HL150392), and the Falk Medical Research Trust Catalyst Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complied with all relevant ethical regulations, and was approved by the University of Michigan Institutional Review Board (HUM00179409).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests: The authors have no competing interests.
Contributors: HS, YZ, SN, AH, CH, AAG, GS, SY, KG, JAM, JW, MZ, and YS conducted experiments and analyzed data. HS, YZ, MDM, JSK, and YK conceived the study and analyzed data. All authors participated in writing the manuscript and gave approval before submission.
Funding: The work was supported by a grant from the Rheumatology Research Foundation to JSK and grants from the Michigan Medicine Frankel Cardiovascular Center and A. Alfred Taubman Medical Research Institute to YK and JSK. YZ was supported by a career development grant from the Rheumatology Research Foundation and a grant from the Arthritis National Research Foundation. JAM was partially supported by the VA Healthcare System. JSK was supported by grants from the NIH (R01HL115138), Burroughs Wellcome Fund, and Lupus Research Alliance. YK was supported by the Intramural Research Program of the NIH and NHLBI, Lasker Foundation, NIH (R01HL150392), and the Falk Medical Research Trust Catalyst Award.
Patient and public involvement: Patients and the public were not involved in design, conduct, reporting, or dissemination of this research.
Patient consent for publication: N/A
Ethics approval: This study complied with all relevant ethical regulations, and was approved by the University of Michigan Institutional Review Board (HUM00179409).
Data availability statement: All data relevant to the study are included in the article or uploaded as online supplemental information.
Data Availability
Upon publication in a peer-reviewed journal, data will be made available by the corresponding authors upon request.
